Corrigendum to ‘Multiple sclerosis: New insights and trends’

Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous system. It attacks people from age 20–50 years old and the females' attacks double than males' attacks. MS is an autoimmune disease affecting principally the central nervous system that causes nerve...

Full description

Bibliographic Details
Main Author: Khaled Mohamed Mohamed Koriem
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-05-01
Series:Asian Pacific Journal of Tropical Biomedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2221169117301703
_version_ 1819151787103354880
author Khaled Mohamed Mohamed Koriem
author_facet Khaled Mohamed Mohamed Koriem
author_sort Khaled Mohamed Mohamed Koriem
collection DOAJ
description Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous system. It attacks people from age 20–50 years old and the females' attacks double than males' attacks. MS is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination, followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, muscle spasm, difficulties in movement and unbalance. Many factors may be responsible for MS: microorganism, virus, smoking, stress, environmental toxins, contaminated diet and gout. MS is widely spread in the population in North Europe and this is related to lack of vitamin D due to decrease of sunlight exposure. MS biomarkers include nitric oxide, interleukin-6, nitric oxide synthase, fetuin-A and osteopontin. MS is not a genetic disease (not transferred from parents into next generations) but MS appears when leukocyte antigen system-related genes are changed in human chromosome 6. The physiology of MS patients is controlled by numbers of biological processes such as activation of immune-inflammatory, oxidative and nitrosative stress pathways. MS includes two main steps: (1) myelin sheath destruction and formation of lesions and, (2) inflammation. Four types of MS can be distinguished: relapsing-remitting, primary progressive, secondary progressive and progressive relapsing. Nine treatments have been accepted for relapsing-remitting MS type: interferon β-1a, interferon β-1b, mitoxantrone, natalizumab, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, and alemtuzumab. However, the only treatment used is mitoxantrone for progressive MS with many side effects. Complementary treatments are also used in MS treatments such as vitamin D, Yoga, medicinal plants, oxygen therapy, acupuncture and reflexology.
first_indexed 2024-12-22T14:38:56Z
format Article
id doaj.art-e677eea90d4245b79b96e20fdf399954
institution Directory Open Access Journal
issn 2221-1691
language English
last_indexed 2024-12-22T14:38:56Z
publishDate 2017-05-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Asian Pacific Journal of Tropical Biomedicine
spelling doaj.art-e677eea90d4245b79b96e20fdf3999542022-12-21T18:22:36ZengWolters Kluwer Medknow PublicationsAsian Pacific Journal of Tropical Biomedicine2221-16912017-05-017549350410.1016/j.apjtb.2017.02.001Corrigendum to ‘Multiple sclerosis: New insights and trends’Khaled Mohamed Mohamed KoriemMultiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous system. It attacks people from age 20–50 years old and the females' attacks double than males' attacks. MS is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination, followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, muscle spasm, difficulties in movement and unbalance. Many factors may be responsible for MS: microorganism, virus, smoking, stress, environmental toxins, contaminated diet and gout. MS is widely spread in the population in North Europe and this is related to lack of vitamin D due to decrease of sunlight exposure. MS biomarkers include nitric oxide, interleukin-6, nitric oxide synthase, fetuin-A and osteopontin. MS is not a genetic disease (not transferred from parents into next generations) but MS appears when leukocyte antigen system-related genes are changed in human chromosome 6. The physiology of MS patients is controlled by numbers of biological processes such as activation of immune-inflammatory, oxidative and nitrosative stress pathways. MS includes two main steps: (1) myelin sheath destruction and formation of lesions and, (2) inflammation. Four types of MS can be distinguished: relapsing-remitting, primary progressive, secondary progressive and progressive relapsing. Nine treatments have been accepted for relapsing-remitting MS type: interferon β-1a, interferon β-1b, mitoxantrone, natalizumab, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, and alemtuzumab. However, the only treatment used is mitoxantrone for progressive MS with many side effects. Complementary treatments are also used in MS treatments such as vitamin D, Yoga, medicinal plants, oxygen therapy, acupuncture and reflexology.http://www.sciencedirect.com/science/article/pii/S2221169117301703Multiple sclerosisDiagnosisGeneticsPhysiologyTreatments
spellingShingle Khaled Mohamed Mohamed Koriem
Corrigendum to ‘Multiple sclerosis: New insights and trends’
Asian Pacific Journal of Tropical Biomedicine
Multiple sclerosis
Diagnosis
Genetics
Physiology
Treatments
title Corrigendum to ‘Multiple sclerosis: New insights and trends’
title_full Corrigendum to ‘Multiple sclerosis: New insights and trends’
title_fullStr Corrigendum to ‘Multiple sclerosis: New insights and trends’
title_full_unstemmed Corrigendum to ‘Multiple sclerosis: New insights and trends’
title_short Corrigendum to ‘Multiple sclerosis: New insights and trends’
title_sort corrigendum to multiple sclerosis new insights and trends
topic Multiple sclerosis
Diagnosis
Genetics
Physiology
Treatments
url http://www.sciencedirect.com/science/article/pii/S2221169117301703
work_keys_str_mv AT khaledmohamedmohamedkoriem corrigendumtomultiplesclerosisnewinsightsandtrends